Skip to main content

FDA adds Merck antiviral to COVID-19 tool kit for high-risk adults above 18, amid flurry of positive news on boosters

The U.S. Food and Drug Administration authorized Merck's COVID-19 antiviral for adults who have tested positive for the virus and are at high risk of disease progression early Thursday, granting it a more limited use than the rival one from Pfizer that was authorized on Wednesday.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.